pharma-and-clinical-pharmacy-congress-2016_tracks

15 / 21

Notes:
Page 43
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Pamela Georgina Avila Lamadrid, Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Randomized controlled clinical trial open to 24 weeks of efficiency and safety in outpatient with
obesity grade I and II treated with Clobenzorex vs. Clobenzorex with melatonin
Pamela Georgina Avila Lamadrid, Magdaleno Rodriguez Daniel Roberto, Sanchez Flores Jessica, Cortes Moreno Gabriela Yanet and Lara Padilla Eleazar
Instituto Politecnico Nacional, Mexico
Introduction: Obesity is a disease characterized by the excess of adipose tissue (fat) in the body. Such disease is determined in
adult persons when there is a Body Mass Index (BMI) is equal or higher than 30 kg/m2.
Purpose: To evaluate the efficacy and safety of Clobenzorex 60 mg/Melatonin 3 mg (morning or night) against to Clobenzorex
60 mg in Mexicans with exogenous obesity during 24 weeks.
Methodology: It was a longitudinal, prospective and comparative study. This study was conducted under 180 exogenous
obese patients, administered: (1) Treatment “A” (Clobenzorex 60 mg/Melatonin 3 mg 1 capsule VO, morning), (2) Treatment
“B” (Clobenzorex 60 mg/capsule VO Melatonin 3 mg one night) or (3) Treatment “C” (60 mg 1 capsule Clobenzorex VO,
morning). Efficacy was evaluated by weight loss (kg), BMI, waist-to-hip ratio (WHR) and percentage of body fat. On the other
hand safety was evaluated by recording adverse events occurred.
Results: The treatment “A” causes polydipsia, xerostomia and headache, treatment “B” had a safety advantage for shorter
duration and number of adverse events. Finally, “C” treatment compared to “A” and “B”” treatment, had the lowest rate of
adverse effects by causing only one, which could be polydipsia, headache or constipation.
Conclusion & Significance: All treatments were clinically effective. Greater reduction of the WHR and waist circumference
was observed when using Clobenzorex. However, Clobenzorex/Melatonin (night) resulted safer due to the lower number and
duration of adverse events.
Biography
Pamela Georgina Avila Lamadrid is currently a Medical student of Superior School of Medicine (Escuela Superior de Medicina) at Instituto Politecnico Nacional,
Mexico. She is a Junior Researcher who has been working at the Obesity Center of the School since 2016 on different research lines regarding obesity, diabetes,
fatty liver, metabolic syndrome and hypertension. Her most important recent research is focused on drug effectiveness and security for obesity and fatty liver
treatment.